Roche has effectively acquired LumiraDx's Point of Care technology, having obtained all necessary antitrust and regulatory clearances. Roche will integrate LumiraDx’s innovative multi-assay point-of-care platform into its global organization, enhancing its diagnostics portfolio. The platform consolidates a wide range of immunoassay and clinical chemistry tests on a single instrument, with potential future expansion into molecular testing. This acquisition is expected to significantly bolster Roche’s capabilities in decentralized patient care, providing timely and actionable diagnostic results globally, particularly in primary care and low- and middle-income countries.
Founded in 1896 in Basel, Switzerland, Roche has grown into the world’s largest biotechnology company and a global leader in in-vitro diagnostics. The company is renowned for its commitment to scientific excellence and personalized healthcare. As part of the acquisition, Roche will continue its partnership with the Bill and Melinda Gates Foundation to develop a rapid point-of-care molecular tuberculosis test, aiming to address the global gap in tuberculosis diagnosis and treatment. This acquisition aligns with Roche’s long-term vision of improving global healthcare access and sustainability, as evidenced by its consistent recognition in the Dow Jones Sustainability Indices.
